European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases

Journal of Crohn's and Colitis

Volumn 9, Issue 3, 2015, Pages 211-222

  Dignass, Axel U ^a,m   Gasche, Christoph ^b   Bettenworth, Dominik ^c   Birgegård, Gunnar ^d   Danese, Silvio ^e   Gisbert, Javier P ^f   Gomollon, Fernando ^g   Iqbal, Tariq ^h   Katsanos, Konstantinos ⁱ   Koutroubakis, Ioannis ^j   Magro, Fernando ^k   Savoye, Guillaume ^l   Stein, Jürgen ^m   Vavricka, Stephan ⁿ  

^a AGAPLESION MARKUS KRANKENHAUS   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UPPSALA UNIVERSITY   (Sweden)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^j UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^k HOSPITAL DE SÃO JOÃO   (Portugal)

^l ROUEN UNIVERSITY HOSPITAL   (France)

^m Crohn Colitis Center Frankfurt   (Germany)

ⁿ TRIEMLI HOSPITAL   (Switzerland)

more..

Author keywords

Anaemia; Anaemia of chronic disease; Crohn's disease; Inflammatory bowel disease; Iron deficiency; Transferrin saturation; Ulcerative colitis

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; INFLIXIMAB; IRON; TRANSFERRIN; TRACE ELEMENT; VITAMIN;

ARTICLE; BLOOD TRANSFUSION; COMORBIDITY; CROHN DISEASE; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; FOLIC ACID DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTESTINE FLORA; IRON DEFICIENCY ANEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RECTUM HEMORRHAGE; RECURRENT DISEASE; RISK FACTOR; TRANSFERRIN BLOOD LEVEL; ULCERATIVE COLITIS; ANEMIA; ANEMIA, IRON-DEFICIENCY; COMPLICATION; CONSENSUS DEVELOPMENT; DEFICIENCY; ERYTHROCYTE TRANSFUSION; INFLAMMATORY BOWEL DISEASES; MULTIMODALITY CANCER THERAPY;

ANEMIA; ANEMIA, IRON-DEFICIENCY; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; ERYTHROCYTE TRANSFUSION; HEMATINICS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRON; TRACE ELEMENTS; VITAMINS;

EID: 84928603336     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jju009     Document Type: Article

References (132)

1. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis 2000;6:142-50
2. Kulnigg S, Gasche C. Systematic review: managing anemia in Crohn's disease. Aliment Pharmacol Ther 2006;24:1507-23
3. Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008;103:1299-307
4. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010;7:599-610
5. Gomollon F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009;15:4659-65
6. Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health 2005;8:629-38
7. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-53
8. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979-83
9. Anonymous. Levels of evidence and grades of recommendation. 2011. http://www.cebm.net/mod_product/design/files/CEBM-Levels-of-Evidence-2.1.pdf Accessed October 3, 2014
10. WHO, UNICEF, UNU. Iron Deficiency Anemia: Assessment, Prevention and Control. Report of a joint WHO/UNICEF/UNU consultation. Geneva:World Health Organization; 1998
11. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107: 1747-50
12. Perry GS, Byers T, Yip R, Margen S. Iron nutrition does not account for the hemoglobin differences between blacks and whites. J Nutr 1992;122:1417-24
13. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004;116 Suppl 7A:44S-9S
14. Bergamaschi G, Di SA, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica 2010;95:199-205
15. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:513-9
16. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55 Suppl 1:i1-15
17. Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition 2006;22:1210-3
18. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23
19. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Kefalogiannis G, Niniraki M, Kouroumalis EA. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohns Colitis 2011;5:295-300
20. Oustamanolakis P, Koutroubakis IE, Kouroumalis EA. Diagnosing anemia in inflammatory bowel disease: beyond the established markers. J Crohns Colitis 2011;5:381-91
21. Gasche C. Anemia in Inflammatory Bowel Disease. Bremen, Germany: Uni-med; 2008
22. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003;329:9-22
23. Hansen TM, Hansen NE, Birgens HS, Holund B, Lorenzen I. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis. Scand J Rheumatol 1983;12:353-9
24. Bartels U, Pedersen NS, Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol 1978;13:649-56
25. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anemia, and inflammatory bowel diseases. Gut 2004;53:1190-7
26. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1982;1:652-5
27. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anemic iron-deficient adolescent girls. Lancet 1996;348:992-6
28. Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Iron intake and risk of ovulatory infertility. Obstet Gynecol 2006;108:1145-52
29. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011;118:3222-7
30. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011;86:923-7
31. Oustamanolakis P, Koutroubakis IE. Soluble transferrin receptor-ferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. Inflamm Bowel Dis 2011;17:E158-9
32. Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor [sTfR] and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia: a meta-analysis. Am J Clin Pathol 2012;138:642-9
33. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006;12:1101-6
34. Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013;88:97-101
35. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006;12:123-30
36. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141:846-53, e841-42
37. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48
38. Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women-PREFER, a randomized, placebo-controlled study. PLoS One 2014;9:e94217
39. Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001;96:2382-7
40. Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:269-77
41. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose [FERINJECT] randomized controlled trial. Am J Gastroenterol 2008;103:1182-92
42. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014;54:306-15
43. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anemia. Drugs 2009;69:739-56
44. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992;42:1439-52
45. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997;126:782-7
46. Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 1999;60:262-7
47. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-9
48. Schroder O, Schrott M, Blumenstein I, Jahnel J, Dignass AU, Stein J. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol 2004;42:663-7
49. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44:838-45
50. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. ScandJGastroenterol 2005;40:1058-65
51. Koutroubakis IE, Karmiris K, Makreas S, Xidakis C, Niniraki M, Kouroumalis EA. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anemia: a pilot study. Eur J Gastroenterol Hepatol 2006;18:421-5
52. Kulnigg-Dabsch S, Schmid W, Howaldt S, et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled ThromboVIT trial. Inflamm Bowel Dis 2013;19:1609-16
53. Hassan N, Cahill J, Rajasekaran S, Kovey K. Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: first case series. Ann Pharmacother 2011;45:e63
54. Ford D, Cohen M, Strauss W, et al. Evaluation of ferumoxytol treatment for iron deficiency anemia in patients with gastrointestinal disorders who have a history of unsatisfactory oral iron therapy: results of a Phase III, randomized, placebo-controlled trial. Gastroenterology 2013;144:S754
55. Koutroubakis IE, Oustamanolakis P, Karakoidas C, Mantzaris GJ, Kouroumalis EA. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci 2010;55:2327-31
56. Khalil A, Goodhand JR, Wahed M, Yeung J, Ali FR, Rampton DS. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. Eur J Gastroenterol Hepatol 2011;23:1029-35
57. Cavill I, Auerbach M, Bailie GR, et al. Iron and the anemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 2006;22:731-7
58. Ganzoni AM. [Intravenous iron-dextran: therapeutic and experimental possibilities]. Schweiz Med Wochenschr 1970;100:301-3
59. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, noninferiority study of intravenous iron isomaltoside 1, 000 [Monofer] compared with oral iron for treatment of anemia in IBD [PROCEED]. Am J Gastroenterol 2013;108:1877-88
60. World Health Organization. Nutritional Anemias. Geneva: World Health Organization; 1968
61. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis 2012;6:267-75
62. De Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 2005;22:1097-105
63. Seril DN, Liao J, West AB, Yang GY. High-iron diet: foe or feat in ulcerative colitis and ulcerative colitis-associated carcinogenesis. JClin, Gastroenterol 2006;40:391-7
64. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci 2002;47:1266-78
65. Oldenburg B, Berge Henegouwen GP, Rennick D, Van Asbeck BS, Koningsberger JC. Iron supplementation affects the production of pro-inflammatory cytokines in IL-10 deficient mice. Eur J Clin Invest 2000;30:505-10
66. Seril DN, Liao J, Yang CS, Yang GY. Systemic iron supplementation replenishes iron stores without enhancing colon carcinogenesis in murine models of ulcerative colitis: comparison with iron-enriched diet. Dig Dis Sci 2005;50:696-707
67. Werner T, Wagner SJ, Martinez I, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut 2011;60:325-33
68. Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire. Am J Clin Nutr 2010;92:1406-15
69. Gasche C, Ahmad T, Tulassay Z, et al. Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: results from a Phase-3 Clinical Trial Program. Inflamm Bowel Dis (Epub ahead of print)
70. Finch C. Regulators of iron balance in humans. Blood 1994;84:1697-702
71. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012;61:933-52
72. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005 118:1142-7
73. Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM. Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial. Am J Clin Nutr 2003;78:145-53
74. Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009;104:1460-7
75. Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol 2001;96:2296-8
76. Oldenburg B, Koningsberger JC, Berge Henegouwen GP, Van Asbeck BS, Marx JJ. Iron and inflammatory bowel disease. Aliment Pharmacol Ther 2001;15:429-38
77. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol 2007;13:4798-806
78. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004;39:454-8
79. Weinstock LB, Bosworth BP, Scherl EJ, et al. Crohn's disease is associated with restless legs syndrome. Inflamm Bowel Dis 2010;16:275-9
80. Brownlie Tt, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004;79:437-43
81. Brutsaert TD, Hernandez-Cordero S, Rivera J, Viola T, Hughes G, Haas JD. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr 2003;77:441-8
82. Hinton PS, Sinclair LM. Iron supplementation maintains ventilatory threshold and improves energetic efficiency in iron-deficient nonanemic athletes. Eur J Clin Nutr 2007;61:30-9
83. Verdon F, Burnand B, Stubi CL, et al. Iron supplementation for unexplained fatigue in non-anemic women: double blind randomised placebo controlled trial. BMJ 2003;326:1124
84. Lozoff B, Jimenez E, Smith JB. Double burden of iron deficiency in infancy and low socioeconomic status: a longitudinal analysis of cognitive test scores to age 19 years. Arch Pediatr Adolesc Med 2006;160:1108-13
85. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm 2005;11:565-74
86. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012;380:2129-43
87. Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica 2010;95:175-8
88. Tsiopoulos FD, Manolakis AC, Kapsoritakis AN, Psychos AK, Potamianos SP. Autoimmune hemolytic anemia and ophthalmic artery thrombosis preceding the intestinal manifestations of Crohn's disease. Inflamm Bowel Dis 2009;15:487-8
89. Hagel S, Bruns T, Kantowski M, Fix P, Seidel T, Stallmach A. Cholestatic hepatitis, acute acalculous cholecystitis, and hemolytic anemia: primary Epstein-Barr virus infection under azathioprine. Inflamm Bowel Dis 2009;15:1613-6
90. Mattis LE, Saavedra JM, Shan H, Shirey RS, Powell E, Oliva-Hemker MM. Life-threatening ceftriaxone-induced immune hemolytic anemia in a child with Crohn's disease. Clin Pediatr [Phila] 2004;43:175-8
91. Wiesen A, Wiesen J, Limaye S, Kaushik N. Mesalazine-induced aplastic anemia. Am J Gastroenterol 2009;104:1063
92. Kishikawa H, Nishida J, Nakano M, Hirano E, Morishita T, Ishii H. Ulcerative colitis associated with aplastic anemia. Dig Dis Sci 2003;48:1376-9
93. Naithani R, Mahapatra M, Kumar R, Rai S. Aplastic anemia and Crohn's disease-coincidence or association? Indian J Gastroenterol 2005;24:183
94. Yu LZ, Qian S, Hong M, Liu P, Li J. A case of ulcerative colitis associated with autoimmune hemolytic anemia successfully treated by autologous hematopoietic stem cell transplantation. Am J Gastroenterol 2010;105:2302-4
95. Leo Carnerero E, Aoufi S, Montero Cuadrado I, Herrera Martin P, Herrera Justiniano JM. Autoimmune hemolytic anemia associated with ulcerative colitis: response to infliximab. Am J Gastroenterol 2009;104:2370-1
96. Kallel L, Boubaker J, Filali A. Autoimmune hemolytic anemia in a young adult with Crohn's disease and primary sclerosing cholangitis: an unusual association. J Crohns Colitis 2009;3:134-5
97. Hochman JA. Autoimmune hemolytic anemia associated with Crohn's disease. Inflamm Bowel Dis 2002;8:98-100
98. Wu CH, Wong JM, Hsieh SC, Yu CL. An unusual case of ulcerative colitis with concurrent extraintestinal manifestations of primary sclerosing cholangitis, thromboembolism, hemolytic anemia, and hemochromatosis. J Microbiol Immunol Infect 2005;38:224-9
99. Molnar T, Farkas K, Szepes Z, Nagy F, Wittmann T. Autoimmune hemolytic anemia associated with ulcerative colitis: the most important step is to induce complete remission. Am J Gastroenterol 2010;105:1203-4; author reply 1204
100. Doyle MK, Rahman MU, Han C, et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum 2009;39:123-31
101. Braun J, van der Heijde D, Doyle MK, et al. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 2009;61:1032-6
102. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica 2010;95:199-205
103. Katsanos K, Cavalier E, Ferrante M, et al. Intravenous iron therapy restores functional iron deficiency induced by infliximab. J Crohns Colitis 2007;1:97-105
104. Domenech E, Manosa M, Masnou H, et al. Infliximab for the treatment of chronic anemia in Crohn's disease. Am J Gastroenterol 2005;100:496
105. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996;334:619-23
106. Yakut M, Ustun Y, Kabacam G, Soykan I. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med 2010;21:320-3
107. Alkhouri RH, Hashmi H, Baker RD, Gelfond D, Baker SS. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013;56:89-92
108. Green R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. Am J Clin Nutr 2011;94:666S-672S
109. Otsubo H, Kaito K, Sekita T, Shimada T, Kobayashi M, Hosoya T. Mesalazine-associated severe aplastic anemia successfully treated with antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor. Int J Hematol 1998;68:445-8
110. van Hees PA, van Elferen LW, van Rossum JM, van Tongeren JH. Hemolysis during salicylazosulfapyridine therapy. Am J Gastroenterol 1978;70:501-5
111. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21
112. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 199;340:409-17
113. Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis 2010;4:427-430
114. Garcia-Erce JA, Gomollon F, Munoz M. Blood transfusion for the treatment of acute anemia in inflammatory bowel disease and other digestive diseases. World J Gastroenterol 2009;15:4686-94
115. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006;105:198-208
116. Roghi A, Cappellini MD, Wood JC, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol 2010;89:585-9
117. Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000;135:256-62
118. Krzystek-Korpacka M, Neubauer K, Berdowska I, Zielinski B, Paradowski L, Gamian A. Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of anemia and treatment. Inflamm Bowel Dis 2010;16:1467-75
119. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51:143-6
120. DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ. Macrocytosis and pure RBC anemia caused by azathioprine. Am J Dis Child 1980;134:377-9
121. Formea CM, Myers-Huentelman H, Wu R, et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am J Transplant 2004;4:1810-7
122. Agrawal A, Parrott NR, Riad HN, Augustine T. Azathioprineinduced pure red cell aplasia: case report and review. Transplant Proc 2004;36:2689-91
123. Old CW, Flannery EP, Grogan TM, Stone WH, San Antonio RP. Azathioprine-induced pure red blood cell aplasia. JAMA 1978;240:552-4
124. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase [TPMT] genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:395-400
125. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002,;50:485-9
126. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30
127. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-8
128. Cheung ST, Allan RN. Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Eur J Gastroenterol Hepatol 2003;15:1245-7
129. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14:407-17
130. Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M. Three novel thiopurine S-methyltransferase allelic variants [TPMT*20, *21, *22]-association with decreased enzyme function. Hum Mutat 2006;27:976
131. Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther 2009;29:459-69
132. Sandborn WJ. Pharmacogenomics and IBD: TPMT and thiopurines. Inflamm Bowel Dis 2004;10 Suppl 1:S35-;7